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The combined use of enamel
matrix proteins anda tetracycline-
coated expanded
polytetrafluoroethylene barrier
membrane in the treatment of
intra-osseous defects
Sipos PM, Loos BG, Abbas F, Timmerman MF, van der Velden U. The combined use of
enamel matrix proteins and a tetracycline-coated expanded polytetrafluoroethylene
barrier membrane in the treatment of intra-osseous defects. J Clin Periodontol 2005;
32: 765–772. doi: 10.1111/j.1600-051X.2005.00754.x.r Blackwell Munksgaard 2005.
Abstract
Objectives: The purpose of this split-mouth study was to evaluate the clinical
response of enamel matrix proteins (EMPs, Emdogain Gel
s
) in intra-osseous defects
with or without a combined application of a tetracycline-coated expanded
polytetrafluoroethylene barrier membrane (e-PTFE, Gore-Tex
s
).
Methods: Twelve pairs of intra-osseous periodontal defects in 11 patients received
the application of EMPs on the exposed root surface (EMP). One of the two defects
received randomly, as an adjunct to EMP treatment, a tetracycline-coated e-PTFE
membrane (MEMP). At baseline, 6- and 12-month probing pocket depth (PPD),
clinical attachment level (CAL) and probing bone level (PBL) were measured.
Results: After 12 months, the EMP defects showed a significant mean PPD reduction
of 2.86  0.75mm, a mean gain in CAL of 1.28  2.04mm, a mean PBL gain of
1.63  1.21mm and a mean increase of recession (REC) of 1.56  2.30mm. The
MEMP defects showed a significant mean PPD reduction of 3.02  1.55mm, a mean
gain in CAL of 1.65  1.29mm, a mean PBL gain of 1.58  1.92mm and a mean
increase of REC of 1.38  1.63mm. Except for significantly more post-operative
discomfort at the MEMP sites, no significant differences were found between EMP and
MEMP defects.
Conclusion: Within the limits of this study, it is concluded that in the treatment of
intra-osseous defects with EMP, the adjunctive use of a tetracycline-coated e-PTFE
membrane failed to show more gain of CAL and PBL.
Key words: barrier membranes; enamel matrix
proteins; GTR; intra-osseous defects;
tetracycline
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A relatively new biological concept in
the attempts to obtain periodontal regen-
eration is the use of enamel matrix
proteins (EMP). In vitro studies have
demonstrated that EMP stimulate
attachment, growth and metabolism of
periodontal ligament fibroblasts (Hoang
et al. 2000, Van der Pauw et al. 2000,
Lyngstadaas et al. 2001), but not
gingival fibroblasts (Gestrelius et al.
1997b). EMP absorb to hydroxyapatite,
collagen and denuded dental roots (Ges-
trelius et al. 1997a). Furthermore, it has
been suggested that EMP applied to
teeth may have an inhibitory effect on
the formation of the oral biofilm
(Arweiler et al. 2002, Spahr et al.
2002).
Comparable reduction of probing
pocket depth (PPD), a gain in probing
attachment level and, in some studies, a
gain in alveolar bone have been accom-
plished after guided tissue regeneration
(GTR) and application of EMP (Cortel-
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lini et al. 1996, Bouchard et al. 1997,
Caffesse et al. 1997, Hammarstro¨m
et al. 1997, Heden et al. 1999, Heijl
1997, Heijl et al. 1997, Smith MacDo-
nald et al. 1998, Mellonig 1999, Pontor-
iero et al. 1999, Sculean et al.
1999a, b, c, Heden 2000, Froum et al.
2001, Loos et al. 2002, Abbas et al.
2003). However, a variation of clinical
outcome and predictability is reported for
GTR as well as EMP (Tonetti & Cortel-
lini 1997, Tonetti et al. 1998, 2002,
Heden et al. 1999, Loos et al. 2002).
In contrast to EMP, barrier mem-
branes are thought to control healing
dynamics by covering the periodontal
defect. The gingival tissues (epithelium
and connective tissue) are prevented
from contacting the root surface during
early healing, and may thus provide
space for cells originating from the
periodontal ligament to re-populate the
previously affected root surface. This
may induce regeneration of the lost
periodontal tissues (Gottlow et al.
1986). One important aspect jeopardiz-
ing a predictable and successful out-
come concerns bacterial infection of
the healing intra-osseous defect (Slots
et al. 1999). It has been suggested that
the immediate post-operative infection
by periodontal pathogens of the treated
defect and colonization of the mem-
brane itself may be one reason for lack
of results in some cases (Selvig et al.
1992, Mombelli et al. 1993). For exam-
ple, periodontal pathogens may colonize
membranes within 3min. of intra-oral
manipulation. The presence of bacteria
on the membrane surface facing the
gingiva at 6 weeks postoperatively has
been shown to be a statistically signifi-
cant negative predictor of gain in clin-
ical attachment (Nowzari et al. 1996).
Controlling the bacterial colonization
in the early healing phase and reducing
the spread of infections may increase the
predictability of results (Zucchelli et al.
2000). Several antimicrobial agents
have been shown to be inhibitory for
bacteria associated with destructive
periodontal disease (Walker et al.
1985). The use of systemic antibiotics
have therefore been propagated by many
researchers investigating regenerative
procedures for the treatment of intra-
osseous defects (Van Winkelhoff et al.
1996, Cortellini & Tonetti 2000, Korn-
man & Robertson 2000). Compared
with systemically delivered antibiotics,
locally controlled-release delivery
devices applied professionally may
exhibit several benefits: independence
of patient compliance, enhanced or
improved pharmacokinetic response,
greater access and the ability to position
the drug adjacent to the disease and to
deliver a lower total dosage of the drug
to the patient but giving a more con-
trolled concentration at the diseased site
(Goodson 1989). Few studies are known
using local antimicrobial devices in the
treatment of intra-osseous defects. The
use of topical 25% metronidazole gel in
GTR was shown to be more effective in
preventing membrane contamination,
but did not improve clinical outcomes
(Zucchelli et al. 1999). A study using a
tetracycline-coated expanded polytetra-
fluoroethylene (e-PTFE) barrier mem-
brane suggested that the antimicrobial
properties of tetracycline during initial
healing could result in additional gain of
clinical periodontal attachment (Zarkesh
et al. 1999).
Controlled clinical studies comparing
the use of EMP and bioresorbable
membranes and combinations of
both showed no significant difference
between any treatment modality in gain
of clinical attachment and bone (Scu-
lean et al. 1999a, b, c, 2000, 2001a, b,
Silvestri et al. 2000). However, in these
studies, the adjunctive use of tetracy-
cline attached to an e-PTFE barrier
membrane to control early membrane
infection has not been investigated.
Therefore, the aim of this study was
to evaluate, in a split-mouth rando-
mized-controlled clinical trial, the clin-
ical response of EMP in the treatment of
intra-osseous defects with or without a
GTR technique using a tetracycline-
coated e-PTFE barrier membrane.
Material and Methods
Subjects and inclusion criteria
Initially, 18 consecutive untreated perio-
dontitis patients, in the age range of
18–55 years, referred to the Department
of Periodontology at ACTA, were
recruited, in good general health, with
at least two intra-osseous defects ful-
filling the criteria of X6mm pocket
depth and X4mm radiographic depth
not adjacent to a molar furcation site.
The defects could be located on any
tooth, except the upper molars. The
teeth at the defect sites had to have vital
pulps, as assessed by sensitivity to a
cold test using ethyl chloride to exclude
endodontic complications. Smoking
habits were recorded, and smoking was
quantified as the number of packyears
(number of packs of cigarettes smoked
per day  number of years smoked)
(Grossi et al. 1995). The patients were
informed about the aim of the study
verbally and in writing, and they signed
an informed consent before participation.
Pre-trial treatment
Each patient received a minimum of 6 h
of pre-trial initial treatment consisting
of meticulous oral hygiene instructions
and supra- and subgingival debridement
with manual and ultrasonic instruments
using local anaesthetics. Patients who
were culture positive for Actinobacillus
actinomycetemcomitans 3 months after
initial therapy received treatment of 1 h
by means of re-scaling and root planing
in conjunction with systemic antibiotics
(375mg amoxicillin TID and 250mg
metronidazole TID) for 1 week. Sites
unrelated to the selected intra-osseous
defects that showed at re-evaluation, i.e.
3 months after the completion of the
initial therapy, residual PPD of X6mm
were treated by conventional perio-
dontal surgery. The selected experimen-
tal intra-osseous sites and sites with a
residual PPD of 4–5mm received an
extra session of subgingival debride-
ment under local anaesthetics.
Final patient selection
The subjects had to demonstrate the
ability to perform good oral hygiene,
by having a full-mouth plaque score of
o20% in two consecutive screening
sessions prior to the final selection; if
not, they were excluded from the study.
Patients using antibiotics were admitted
for the final selection at least 3 months
after the last use of antibiotics. Only
patients who showed at the final selec-
tion, after the pre-trial treatment, two
non-adjacent, inter-proximal intra-oss-
eous defects with a probing depth from
the buccal and/or lingual aspect ofX6mm
were included. The defects were required
to show an angular bony defect ofX4mm
on a new radiograph made at the definitive
selection appointment.
Clinical measurements
The level of oral hygiene and the degree
of inflammation during the pre-trial per-
iod as well as during the actual trial was
evaluated on the basis of full-mouth
plaque and bleeding scores. After appli-
cation of erythrosine dye (Merck KGaA,
Darmstadt, Germany), the presence or
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absence of plaque along the gingival
margin was scored at the mesiobuccal,
mid-buccal, distobuccal, mesiolingual,
mid-lingual and distolingual sites of all
teeth. Full-mouth plaque scores were
calculated as the percentage of sites
harbouring plaque. Full-mouth bleeding
scores were calculated as the percentage
of sites, measured at six sites for all
teeth, that bled upon probing to the
bottom of the pocket with a manual
PQW probe (Hu-Friedy, Zweignieder-
lassung, Leimen, Germany). Clinical
measurements of the experimental sites
at baseline (i.e. directly prior to sur-
gery), 6 and 12 months were performed
by the same calibrated investigator
(B. G. L.), who was blinded with respect
to treatment modality. PPDs were mea-
sured with the use of a force-controlled
probe (parallel tine, 0.25N, 127N/cm2)




FL, USA) (Gibbs et al. 1988). PPD and
clinical attachment level (CAL) mea-
surements were carried out at the
selected intra-osseous defects from the
buccal and lingual aspects. CAL mea-
surements were performed from a cus-
tom-made stent margin. PPD and CAL
measurements were performed in dupli-




quently the mean of the two values
was calculated. Probing bone level
(PBL) measurements were performed
with a PCP UNC-15 probe (Hu-Friedy)
after application of local anaesthesia
using as much force as needed to feel
a bony resistance, and recorded to the
nearest half millimetre with the stent
margin as reference.
Membrane preparation
The tetracycline-coated e-PTFE mem-
branes were prepared in the following
way: type GTA 1 and GTA 2 e-PTFE
(Gore-Tex
s
, W. L. Gore & Associates
Inc., Flagstaff, AZ, USA) barrier mem-
branes were submerged for 1min. in 5%
solution of tridodecylmethylammonium
chloride (TDMAC) in absolute alcohol.
After drying at room temperature, the
TDMAC-coated membranes were
immersed for 1min. into a freshly pre-
pared 3% tetracycline solution (250mg
dissolved in 7.5ml distilled water, pH
adjusted from 1.7 to 9.5 using sodium
hydrochloride) and dried at room tem-
perature. Tetracycline-coated e-PTFE
membranes were stored in separate ster-
ile containers in the dark at 101C (Zar-
kesh et al. 1999).
Surgical procedures
Each patient received a prescription of
0.2% chlorhexidine rinses (Corsodyl
s
,
GSK, Zeist, The Netherlands) for two
rinses a day to be started 1 day before
the planned surgical procedure. All sur-
gical procedures were performed by one
experienced clinician (F. A.). Full-thick-
ness flaps were raised around both
defects. The modified or simplified
papilla preservation technique was
used depending on the width of the
inter-dental space (Cortellini & Tonetti
2000). The flaps were extended to
include at least one tooth mesial and
distal to the experimental defect
involved. These adjacent teeth would
provide anchoring for the tetracycline-
coated barrier membrane. In addition,
the flaps were extended apically to
ensure that the barrier at placement
would rest on bone along its entire
peri-defect extension. Granulation tissue
was removed, and root surfaces were
planed with hand instruments and ultra-
sonics with saline cooling (EMS
s
, Elec-
tro Medical Systems, Nyon,
Switzerland). In order not to compro-
mise the vascularization of the flaps, no
horizontal periostal-releasing incisions
were performed.
Clinical measurements to describe
the defect were recorded, including
the number of walls, and the width of
the defect. To evaluate to what extent
measurements of the clinical PBL reflect
the actual bone level, surgical PBLs
(SPBL) were measured during surgery
by measuring from the deepest point of
the defect with a PCP UNC-15 probe to
the nearest half millimetre with the stent
margin as reference.
By an aselect numbers randomization
procedure, it was determined as to which
defect would receive treatment with
EMP alone or EMP in conjunction with
a membrane (MEMP). For the randomi-
zation procedure, a randomization list
and randomization envelopes were pre-
pared. EMP (Emdogain Gel
s
, Biora AB,
Malmo¨, Sweden) was prepared 15min.
before surgical use. The sites were kept
free from bleeding as much as possible.
The root surface was conditioned for
2min. with 24% ethylenediamine tetra-
aceticacid gel (pH 6.7) (PrefGel
s
, Biora
AB) and after thoroughly rinsing with
sterile saline, EMP was applied on the
exposed root surface followed by sutur-
ing with e-PTFE sutures (Gore-Tex
s
, W.
L. Gore & Associates Inc.). For the
MEMP site, a tetracycline-coated
e-PTFE barrier was trimmed for cover-
age of the selected defect and sutured
around the neck of the tooth in a tent-like
fashion and lifted prior to root condition-
ing and application of EMP. Flaps over
both defects were sutured with the inten-
tion to achieve primary closure. The
duration of surgery was recorded for
the EMP and MEMP site separately.
Finally, post-operative instructions for
pain control with acetominophen tablets
(paracetamol 500mg) were provided to
the patient.
Post-operative procedures and follow-up
Each patient was instructed to continue
chlorhexidine rinses for 8 weeks post-
operatively. Control of chlorhexidine
compliance, gentle polishing with mini-
mum amounts of pumice to remove
plaque and chlorhexidine staining were
performed at week 1, 2 and 4 post-
operatively. Sutures were removed after
2 weeks. Sutures that loosened pre-
maturely were removed. The extent of
membrane exposure was recorded in
millimetres with a PQW probe at each
visit. The barrier membranes were
removed in a second-stage surgery after
6 weeks, using local anaesthesia. The
sutures for the second stage were removed
after 1 week. Patients were asked at each
visit up to 2 months whether they felt any
discomfort at one or both of the treated
sites. The amount of acetominophen used
by the patient was documented. Oral
hygiene compliance was checked, and
gentle supragingival scaling and careful
polishing of the tooth surfaces were per-
formed monthly until month 6, followed
by checkups at months 9 and 12.
Statistical analysis
From the baseline buccal and lingual
mean PPD measurements of each intra-
osseous lesion, the deepest was selected
for further analysis throughout the
study. From the PPD and CAL measure-
ments, changes in the location of the
gingival margin (gingival recession)
were calculated (REC). The primary
outcome variables were CAL and PBL.
Furthermore, full-mouth percentual
scores of plaque and bleeding were
calculated as a marker of periodontal
condition and patient compliance. EMP
and MEMP sites were compared within
patients. A 2  2 level repeated measure
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analysis was used to analyse the effect
of several covariates on changes in CAL
and PBL by entering baseline and
12-month values as dependent variables
and entering baseline full-mouth plaque
and bleeding scores, baseline PPD, defect
dimensions, receiving antibiotics, smok-
ing, age and gender as covariates. Since
none of the covariates had a significant
association with any of the effects in the
analyses, all further analyses were per-
formed using Wilcoxon tests, comparing
various parameters at each assessment
and comparing different assessments
through time within defects.
Defects were paired in each patient.
In one patient, two pairs were available;
all other pairs were located in 10 differ-
ent patients. The extra pair of defects in
the 11th patient was entered into the
analysis without further correction as
the non-parametric analyses do not allow
for it. Since the ratio is 1 extra against 10
in separate patients, the possible disturb-
ing influence of within-patient depen-
dence of the two pairs of defects could
be considered as minor. P-valueso0.05
were accepted as statistically significant.
The power of the study, given 2mm as a
significant difference in increments
(from baseline to 12 months) between
treatments, was calculated to be 0.8 for
both CAL and PBL.
Results
From the initial 18 selected subjects, 11
patients (four male, seven female) with,
in total, 24 sites (one patient had two
paired defects), entered and completed
the study. Reasons for withdrawal were
insufficient time (n5 2), travelling dis-
tance (n5 1) and insufficient compli-
ance (n5 1). Three patients showed
reduction of PPD and radiographic
defect depth after the pre-trial treatment,
to such an extent that they did not fulfil
the inclusion criteria anymore.
At baseline, the mean age of the
patients was 34.8 years (range 18.0–
51.0 years). Three patients were smo-
kers with a mean of 7.5 packyears
(range 2.0–20.0 packyears); one patient
was a former smoker and stopped smok-
ing 26 years ago (8.0 packyears). Seven
out of the 11 patients entering the study
who were culture positive for A. actino-
mycetemcomitans after initial therapy
were treated by means of re-scaling
and root planing in conjunction with
systemic amoxicillin and metronidazole.
The patients maintained good levels
of oral hygiene throughout the study. At
baseline, the mean full-mouth plaque
score was 5.4% (range 2.0–8.0%) and
the full-mouth bleeding score was 6.7%
(range 1.0–12.0%). At 6 months, the
mean full-mouth plaque score was
11.8% (range 4.0–29.0%) and the
mean full-mouth bleeding score was
3.9 % (range 1.0–7.0%). At 12 months,
the data showed a mean full-mouth
plaque score of 12.5% (range 1.0–
38.0%) and a mean bleeding score of
6.0% (range 1.0–17.0%).
The mean PPD at baseline was 7.0mm
(range 6.0–9.4mm) for the EMP sites and
7.3mm (range 6.1–10.6mm) for the
MEMP sites (Table 1). After 12 months,
the EMP sites showed a mean PPD
reduction of 2.9mm (range 1.8–
4.1mm), a mean gain of CAL of
1.3mm (range 3.5mm loss–4.5mm
gain), a mean gain of PBL of 1.6mm
(range 0.5mm loss–3.0mm gain) and a
mean increase of REC of 1.6mm (range
1.6mm decrease–6.1mm increase). The
MEMP sites showed a mean PPD reduc-
tion of 3.0mm (range 1.1–5.6mm), a
mean gain of CAL of 1.7mm (range
0.1mm–3.9mm), a mean gain of PBL
of 1.6mm (range 0.5 loss–5.5mm
gain) and a mean increase of REC of
1.4mm (range 1.8mm decrease–3.8mm
increase). Again, no statistically signifi-
cant differences in the amount of plaque
and bleeding on a site level were found.
No statistically significant difference
was found between 6 and 12 months
with regard to PPD, CAL, PBL and REC
results. Twelve months after baseline,
the clinical parameters PPD, CAL, PBL
showed a significant improvement,
together with a significantly increased
amount of REC compared with baseline.
However, no statistically significant dif-
ferences were found between the two
treatment modalities EMP and MEMP
(Table 1).
Table 2 shows data on PPD, CAL and
PBL for individual sites. Of the MEMP
sites, none of the defects experienced loss
of clinical attachment, whereas of the
EMP sites, three defects experienced
loss of clinical attachment. In both groups,
only one defect showed loss of PBL.
The anatomy of the intra-osseous
component of the lesions was revealed
to be three walled in all cases (Table 3).
Comparable defect dimensions were
found between EMP and MEMP sites.
The average depth of the defect, mea-
sured from the bottom of the defect to
the top of the crest (intra-osseous com-
ponent), was 4.3mm (range 3.0–
6.5mm) for the EMP sites and 4.3mm
(range 2.5–6.0mm) for the MEMP sites
(Table 2). Evaluation of the PBL and the
SPBL measurements performed on the
day of surgery showed no statistically
significant difference.
In Table 4, the events related to the
surgical treatment are presented. The mean
time needed for the surgical procedures
was 64.8min. (range 35.0–115.0min.)
for the EMP site and 73.3min. (range
28.0–125.0min.) for the MEMP site.
Evaluation of the extent of membrane
exposure 6 weeks after surgery showed
minor membrane exposure (1–2mm) in
eight MEMP sites and more advanced
exposure (X3mm) in two MEMP sites.
Assessment of post-operative discom-
fort showed that one patient had a
loose suture at the EMP site within 1
week, one patient complained about
minor post-operative haemorrhage at
Table 1. Mean values of the clinical parameters  standard deviation at baseline and 6 and 12
months (n5 24 defects in 11 patients)
Baseline 6 months 12 months Difference
baseline – 12 months
p-valuen
PPD
EMP 6.95  1.06 4.69  0.99 4.09  1.17 2.86  0.75 0.0005
MEMP 7.32  1.24 4.37  1.33 4.30  1.08 3.02  1.55 0.0005
CAL
EMP 10.94  1.59 10.00  1.42 9.66  1.75 1.28  2.04 0.0499
MEMP 11.10  1.60 9.65  1.59 9.45  1.74 1.65  1.29 0.0005
PBL
EMP 12.83  2.31 11.42  2.07 11.21  1.88 1.63  1.21 0.0029
MEMP 13.17  1.96 11.92  2.02 11.58  1.88 1.58  1.92 0.0156
REC
EMP 3.99  1.93 5.31  1.08 5.55  1.31 1.56  2.30 0.0454
MEMP 3.77  1.19 5.29  1.48 5.15  1.98 1.38  1.63 0.0226
PPD, probing pocket depth (mm); CAL, clinical attachment level (mm); PBL, probing bone level
(mm); REC: recession (mm); dif, difference. nStatistical testing of differences between baseline and
12 months. Wilcoxon signed rank test.
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the MEMP site for 2 days, one patient
had headaches for 1 week and one
patient had a limited mouth opening
for 1 week. A significantly shorter per-
iod of post-operative pain (mean 1.4
days, range 0–4.0 days) was found in
the EMP sites as compared with the
MEMP sites (mean of 3.5 days, range
1.0–7.0 days). Relatively few days of
discomfort were recorded at the MEMP
sites after membrane removal (mean 0.2
days, range 0–1.0 days). During the first
7 post-operative weeks, a mean of 8.2
tablets (range 0–34 tablets) of acetomi-
nophen was used. Because of the fact
that both treatment modalities were car-
ried out within each patient, the use of
tablets could not be evaluated for EMP
and MEMP sites separately.
The repeated measures analysis did
not show a significant influence of base-
line full-mouth plaque and bleeding
scores, baseline PPD, defect dimen-
sions, receiving of antibiotics, smoking,
age and gender on changes of CAL and
PBL in the analysis.
Discussion
The results of the present investigation
showed that treatment of deep inter-
proximal intra-osseous defects with
EMP with or without an adjunctive
tetracycline-coated barrier membrane
resulted in a statistically significant
mean PPD reduction, gain in attachment
level, gain in bone level and some
gingival recession. There were, how-
ever, no significant differences between
treatment results when comparing the
two treatment modalities. The results of
the present MEMP procedure are com-
parable with other GTR studies (Kersten
et al. 1992, Weltman et al. 1997, May-
field et al. 1998, Zucchelli et al. 1999,
Loos et al. 2002, Minabe et al. 2002). In
contrast to the present findings, much
larger attachment level gains have been
reported by a number of other clinical
trials using GTR (Cortellini et al. 1995),
EMP (Heden et al. 1999, Sculean et al.
1999a, b, c, Heden 2000) or both (Pon-
toriero et al. 1999, Sculean et al. 2001a).
A number of factors that may have
influenced the present results can be
suggested. First, a major difference
between the present study and other
reports relates to the pre-trial treatment.
The current pre-trial treatment included
not only the use of systemic antibiotics
in a number of subjects but also the re-
treatment of the selected experimental
sites by scaling and root planing. It has
been demonstrated that the presence of
A. actinomycetemcomitans may have a
negative influence on the outcome of
periodontal therapy (Machtei et al.
1994). Therefore, it was decided to treat
all patients who were culture positive
for A. actinomycetemcomitans after
initial therapy by means of re-scaling
and root planing in conjunction with
systemic amoxicillin and metronidazole.
This treatment has been shown to be
highly effective in eradicating A. acti-
nomycetemcomitans (Pavicic et al.
1994, Berglundh et al. 1998).
It has been suggested that the pre-trial
treatment negatively influences the
potential of defects to regenerate.
Inflamed lesions may respond more
favourably to surgery than lesions that
have been extensively instrumented
prior to surgery; this may be because
of more open marrow spaces, presence
of immature collagen and tissue factors
(Prichard 1957, Becker et al. 1986,
Becker 1994). Results of the present
study might indeed corroborate the sug-
gestion that extensive scaling and root
planing of an intra-osseous site prior to
regenerative procedures could result in
limited gains in clinical attachment and
new bone. Thus, one has to keep in mind
that extensive pre-trial treatment actu-
ally changes the baseline values of all
Table 2. Individual data on baseline PPD and increments for CAL and PBL for each treatment defect
Site no. MEMP EMP












1 1 36 Mesial 10.6 3.9 5.5 46 Distal 6.3 1.8 3.0
2 2 37 Mesial 6.3 0.1 0.0 46 Mesial 6.0  0.1  0.5
3 3 44 Mesial 7.0 2.9 1.0 36 Mesial 8.1 1.3 3.0
4 4 33 Mesial 7.4 0.5  0.5 43 Mesial 7.6 4.5 1.5
5 5 36 Mesial 7.2 1.8 0.0 46 Mesial 7.2  0.9 0.5
6 6 24 Mesial 7.6 2.6 2.5 15 Distal 6.2 1.1 1.5
7 7 36 Mesial 7.4 1.6 1.5 46 Mesial 7.7 3.0 1.0
8 8 25 Mesial 6.7 3.3 0.0 36 Distal 6.2 1.5 3.0
9 9 46 Distal 6.5 1.7 1.5 36 Mesial 6.3 2.3 0.0
10 10 46 Mesial 8.6 0.5 3.5 36 Mesial 6.0 2.4 2.5
11n 11 37 Distal 6.1 0.3 0.0 46 Distal 9.4  3.5 2.5
12n 11 44 Distal 6.4 0.6 4.0 34 Distal 6.4 2.0 1.5
nTwo pairs of defects in one patient. PPD, probing pocket depth; CAL, clinical attachment level; EMP, enamel matrix protein; MEMP, EMP in
conjunction with a membrane.
Table 3. Clinical characteristics of inter-proximal defects at baseline (n5 24 defects in 11
patients)
EMP MEMP
Defect dimension (mean  SD)
Width defect bucco-lingual in mm (BL) 9.4  0.9 9.2  1.1
Width defect mesio-distal in mm (MD) 3.5  0.9 3.6  1.2
Depth defect buccal in mm 4.8  1.7 4.4  1.0
Depth defect lingual in mm 3.8  1.7 4.1  1.8
Average depth buccal and lingual in mm (D) 4.3  1.3 4.3  1.0
Volume defect in mm3 (BL  MD  D) 144.2  76.2 147.0  72.1
Probing bone level in mm (mean  SD) 12.7  2.3 12.9  2.1
Surgical probing bone level in mm (mean  SD) 12.1  2.3 12.6  2.7
No statistical significant difference between MEMP and EMP defects.
EMP, enamel matrix protein; MEMP, EMP in conjunction with a membrane.
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clinical parameters. Measures of PPD
and CAL will already be more favour-
able than before pre-trial treatment.
When comparing data from studies that
provide no or limited pre-treatment of
experimental sites to studies that per-
form extensive pre-treatment, the base-
line values before all treatment should
be taken into account. In that case,
conclusions should be based on the total
change of parameters because of the
whole series of treatments provided. In
the present study, data do not allow for
such a comparison.
Of the 12 membrane-treated sites, 10
showed exposure of the membrane to
some degree. This occurrence could
have a negative effect on the treatment
outcomes since it has been shown that
exposure of the membrane is related to
less gain in attachment level (Becker
et al. 1988, Cortellini et al. 1990, 1993,
De Sanctis et al. 1996). However, the
tetracycline coat may have limited these
potential negative effects.
Defect morphology has been shown
to influence the potential for regenera-
tion (Renvert et al. 1985, Tonetti et al.
1993, Pontoriero et al. 1999). In the
present study, all lesions were three-
wall intra-osseous defects providing
enough support for the membrane in
order not to collapse, and providing
stabilization of the intra-osseous cloth
formation (Trombelli et al. 1997, May-
field et al. 1998).
No effects of smoking on the CAL or
PBL were found in the present data.
This is in contrast to several previous
studies, which showed that smoker
patients demonstrated less gain in CAL
and PBL than non-smoker patients (e.g.
Tonetti et al. 1998, 2002, Loos et al.
2002). Most likely, the small number of
smokers (n5 3) in the current study is
responsible for this lack of effect.
In the present study, defects were
treated either by EMP or by EMP plus
a membrane coated with tetracycline.
EMP on itself has been reported to
have positive and stimulatory effects
on cells originating from the periodontal
ligament (Van der Pauw et al. 2000,
Lyngstadaas et al. 2001). Moreover,
EMP has inhibitory effects on bacteria,
in particular, it may help to prevent
bacterial colonization of the root surface
that is targeted for regeneration, i.e.
deposition of new cementum with inser-
tion of new periodontal ligament fibres
(Arweiler et al. 2002, Spahr et al. 2002).
It is generally thought that periodontal
ligament cells cannot re-populate the
root surface where bacteria form colo-
nies. While EMP acts supposedly at the
level of the root surface, it has been our
thought that the local application of
tetracycline from the membrane as a
vehicle prevents infection of the blood
clot and infection of flap margins. Tet-
racycline is bacteriostatic and effective
against Gram-positive bacteria, and
many periodontal pathogens (Walker
et al. 1981, Baker et al. 1985a, b).
Tetracycline has the characteristic to
adhere to dentin surfaces, known as
substantivity (Stabholz et al. 1993). It
has been shown to inhibit tissue collage-
nase activity, reduce alveolar bone
resorption (Golub et al. 1984) and pro-
mote fibroblast adhesion and growth
(Terranova et al. 1986). The tetracycline
coat to the membrane has been shown to
have an in vitro antimicrobial activity
for 2–6 weeks, demonstrating its excel-
lent potential to prevent bacterial colo-
nization of the membrane (Zarkesh et al.
1999). The extended antibacterial activ-
ity is obtained by the strong coupling to
the membrane and slow release. Thus, a
combined periodontal ligament stimula-
tory and bacteriostatic approach was
hypothesized to enhance GTR results.
However, this hypothesis is not substan-
tiated by the results; sites treated with
the combination do not respond substan-
tially better than sites treated with EMP
alone.
In conclusion, within the limits of this
study, it is concluded that in the treat-
ment of intra-osseous defects with EMP,
the adjunctive use of a tetracycline-
coated e-PTFE membrane failed to
show more gain of clinical attachment
and bone.
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